Abstract
INTRODUCTION
Hilar cholangiocarcinoma (HC), also known as Klatskin tumor, is a neoplasia arising from the biliary epithe lium at the common hepatic duct bifurcation and may extend to the intrahepatic biliary tree and liver [1, 2] . The only clinical approach that is considered to provide patients with an opportunity for a curative outcome and importantly longterm survival is radical surgical resection [26] . The Bismuth-Corlette classification is the most widely used preoperative system of evaluation that can predict resectability of the lesion and assist in the design of an appropriate surgical approach. A Bismuth type Ⅳ lesion is defined as a tumor that can invade the secondary biliary radicals of both hepatic ducts. During the past decades, accompanied liver resection has been increasingly but gradually recognized as the mainstay of surgical approaches for targeting a Bismuth type Ⅳ tumor [79] , however, there are relatively few studies that have reported in any detail the factors that might affect longterm survival of type Ⅳ HC patients. The overarching aim of the current study was to identify prognostic factors for longterm survival of patients following radical surgery for type Ⅳ HC patients, especially in the setting of lymphovascular invasion (LVI).
MATERIALS AND METHODS

Patient selection
One hundred and fortytwo consecutive patients who underwent radical resection for a pathological diagnosis of type Ⅳ HC at the West China Hospital between January 2000 and February 2012 were enrolled in this study and then reviewed retrospectively. The inclusion criteria included the following: (1) patients who were confirmed with Bismuth type Ⅳ HC by pathological examination; and (2) patients who had undergone radical resection (R0 and R1 resection). The exclusion criteria included the following: (1) patients with gallbladder or intrahepatic cholangiocarcinoma extending to the hilum; (2) presence of a recurrent or metastatic tumor; and (3) R2 resection.
Preoperative workup
Preoperative assessment consisted of acquiring a medical history, physical examination, laboratory tests and radiographic analyses. All patients were evaluated by contrastenhanced ultrasound, contrastenhanced computed tomography or magnetic resonance cho langiography with magnetic resonance cholangio pancreatography with the intention of determining the Bismuth type, the location and extent of the tumor. Biliary drainage, including endoscopic retrograde cho langiopancreatography (ENBD) and percutaneous transhepatic cholangiodrainage (PTCD), was applied in the setting of patients presenting with obstructive jaundice that exceeded 85 μmol/L total bilirubin.
Surgical characteristics of the patients
Based on the relative location and extent of the tumor, different types of resection were performed, which included extrahepatic bile duct resection and en bloc resection of the caudate lobe combined with left hemihepatectomy, right hemihepatectomy and trisectionectomy. In addition, standard regional lymph node dissection should be performed. However, under conditions where tumor metastases to the distant lymph nodes was confirmed during surgery, the surgical intervention was abandoned. According to the American Joint Committee on Cancer (AJCC, 7 th edition), the location of regional lymph nodes was defined as follows: along the common bile duct, cystic duct, portal vein and proper hepatic artery [10] . Vascular resection and reconstruction was only performed when vessels could not be detached from the tumor.
Pathological examination
The pathological evidence of cancer was determined by examination of paraffin sections. All included Bismuth type Ⅳ HC cases were histopathologically confirmed by an experienced pathologist. The presence of tumor emboli within peritumoural endothelial lined spaces was defined as LVI. Resection margin was defined as ductal (i.e., proximal and distal ducts) and with evidence of radial margins. The radial margin was defined as the vertical margin between the tumor edge and dissected periductal structures (e.g., liver parenchyma, blood vessels and adjacent fat tissues). An R0 resection was defined as the presence of a microscopically tumorfree resection margin. An R1 resection was defined as microscopic evidence of tumor tissue at the resection margin, and an R2 resection was defined as macroscopic evidence of tumor tissue at the resection margin. In this study, radical resection was defined as an R0 and R1 resection, a negative resection margin indicated R0 resection, and a positive resection margin indicated an R1 resection.
Follow-up
Whether or not chemotherapy and radiotherapy can benefit HC patients was controversial. None of the patients received postoperative routine chemotherapy or radiotherapy. All enrolled patients had routine follow-ups every 3 mo in the first year and every 6 mo subsequently until at least 5 years after the surgery. The tumor markers [serum levels of carbohydrate antigen 199 (CA199) and carcinoembryonic antigen], liver functions and ultrasonography were conducted. If there was a suspicion of recurrence, contrastenhanced computed tomography or magnetic resonance imaging was further performed. Tumor recurrence was diagnosed on the basis of the combined findings of typical radi ological appearance, quantification of CA199 levels, and clinical presentation. The date of the first suspicious radiological finding was recorded as the date of initial disease recurrence.
Statistical analysis
Patient data were retrospectively collected and statistical analyses were performed with SPSS version 19.0 (SPSS Inc. Chicago, IL, United States). Survival was described using the KaplanMeier method and differences between subgroups were reviewed by the logrank test. Multivariate analysis for prognostic factors was performed using a Cox proportional hazards model to analyze variables whose Pvalue was less than 0.1 in the univariate analysis. Multiple logistical regression analysis was performed to deter mine the association between LVI and potential variables. Twosided P values < 0.05 were considered statistically significant.
RESULTS
Patients' characteristics and operative outcomes
Patients' characteristics and operative outcomes are shown in Table 1 . Altogether 142 patients had a radical resection for type Ⅳ HC, including 75 men and 67 women with a median age of 59 years (range: 2378). Preoperative biliary drainage was carried out in 105 of the 123 obstructive jaundice (total bilirubin > 85 μmol/L) patients, wherein 71 patients underwent PCTD and 34 patients underwent ENBD. Preoperative portal vein embolization was performed in 6 patients.
Radical resection included extrahepatic bile duct resection and en bloc resection of the caudate lobe combined with left hemihepatectomy (n = 73, 51.4%), extended left hemihepatectomy (n = 5, 3.5%), left trisectionectomy (n = 6, 4.2%), right hemihepatectomy (n = 51, 35.9%), extended right hemihepatectomy (n = 5, 3.5%), and right trisectionectomy (n = 2, 1.4%). Regional lymph node dissection was conventionally performed. The R0 resection rate was 75.6%.
Clinicopathological variables influencing DFS and OS
As shown in Table 2 , potential factors that might influence the DFS and OS were analyzed. Univariate analysis demonstrated that age (P = 0.039), preoperative ALB (P = 0.005), resection margin (P < 0.001), histologic grade (P = 0.023), T stage (P = 0.004), N stage (P < 0.001), AJCC stage (P < 0.001), LVI (P < 0.001), tumor size (P < 0.001), portal vein invasion (P = 0.003) and hepatic artery invasion (P = 0.008) significantly influenced DFS. By contrast, patient gender, preoperative CA199, surgical method, perineural invasion and transfusion did not significantly influence DFS. Preoperative ALB (P = 0.009), resection margin (P < 0.001), histologic grade (P = 0.026), T stage (P = 0.001), N stage (P < 0.001), AJCC stage (P < 0.001), LVI (P < 0.001), tumor size (P < 0.001), portal vein invasion (P = 0.002) and hepatic artery invasion (P = 0.013), but not patient age, gender, preoperative CA199, surgical methods, perineural invasion or transfusion, significantly influenced the OS. Multivariate analysis indicated that positive resection margin, higher N stage, tumor size > 30 mm and LVI were adverse factors that influenced DFS and OS.
Association between LVI and N stage and tumor size
LVI was confirmed histologically in 29 (20.4%) of the 142 patients. Table 3 shows the association of LVI with tumor size, N stage and AJCC stage. On univariate analysis, N stage (P < 0.001) and tumor size (P = 0.001), but not AJCC stage, were significantly associated with LVI. Multivariate analysis using a positive group (22.8% vs 0%, P < 0.001) as was the OS (23.8% vs 0%, P < 0.001). Based on the LVI status, N0 stage patients and patients with tumor size ≤ 30 mm were divided into two subgroups, respectively. In the N0 stage subgroups, the 5year DFS rate in the LVI negative group was significantly higher than that in the LVI positive group (31.0% vs 0%, P = 0.002), and the 5year OS rate in the LVI negative group was also significantly higher than that in the LVI positive group (32.4% vs 0%, P = 0.001). In the tumor size ≤ 30 mm subgroups, the 5year DFS rate in the LVI negative group was significantly higher than that in the LVI positive group (31.8% vs 0%, P = 0.003), and the 5year OS rate in the LVI negative group was significantly higher than that in the LVI positive group (34.3% vs 0%, P = 0.006).
DISCUSSION
LVI is recognized as a dismal prognostic factor for OS in patients with breast cancer, colorectal cancer, and esophageal cancer [1114] . However, no studies have yet been published on whether LVI affects the prognosis of Bismuth type Ⅳ HC. Thus, the current study was undertaken to clarify the significance of LVI in type Ⅳ HC patients who had a radical resection. LVI is defined as the involvement of arterial vessels, venules and lymphatic channels [11] , but it is histologically difficult to distinguish, and the American Joint Committee on Cancer/Union Internationale Contre Cancer staging guidelines use the term lymphovascular to refer to those structures [11] . Furthermore, LVI can be confirmed specifically on HE-stained specimens [13] . In our series, LVI was confirmed histopathologically in 29 patients.
It is well recognized that resection margin status is logistic regression model indicated that N1 stage (P = 0.026) and tumor size > 30 mm were significant factors that were associated with LVI in Bismuth type Ⅳ HC. DFS and OS based on LVI status are shown in Figure 1 . The 5year DFS rate in the LVI negative group was significantly higher than that in the LVI A: The 5-yr DFS rate in the LVI negative group was significantly higher than that in the LVI positive group; B: The 5-yr OS rate in the negative group was significantly higher than that in the LVI positive group. LVI: Lymphovascular invasion; DFS: Disease-free survival; OS: Overall survival.
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the most important factor affecting longterm survival outcomes of HC patients [14, 15] , and positive resection margin remains a major dismal prognostic factor for type Ⅳ HC patients. Furthermore, since type Ⅳ HC had been considered unresectable [16] , radical resection performed in such patients is technically challenging. Bracingly, in our center the R0 resection rate is 75.4%. Regional lymph node involvement represents another important dismal prognostic factor in HC patients who had undergone radical resection [17, 18] . Concordantly, the multivariate analysis showed that lymph node metastasis was an adverse factor affecting DFS and OS in type Ⅳ HC. Furthermore, DeOliveira et al [19] proposed a new staging system, in which tumor size > 30 mm was defined as the T3 stage. The choice of 30 mm as a cutoff value for T3 is based on increasing evidence that the smaller the tumor, the better the prognosis [20, 21] . Our results indicated that tumor size > 30 mm had an unfavorable impact on both DFS and OS. More importantly, we found that LVI is a significant adverse prognostic factor influencing DFS and OS in multivariate analysis. To our knowledge, no other reports have shown the correlation between LVI and the prognosis of type Ⅳ HC. Previous studies suggested that LVI may interact with other adverse risk factors, which then have a dismal impact on the OS of esophageal cancer patients [22, 23] . Lee et al [24] found that the presence of LVI correlated with the presence of lymph node metastasis in patients with gastric carcinoma. For different types of cholangiocarcinoma, the effect of LVI on prognosis was also different. Kim et al [25] reported that LVI did not influence the survival of patients with distal cholangiocarcinoma. Fisher et al [26] reported that LVI had an adverse influence on survival of patients with intrahepatic cholangiocarcinoma. Both of studies found that LVI was associated with lymph node metastasis [25, 26] . In our analysis, N1 stage was a significant factor that was associated with LVI in type Ⅳ HC patients. It is generally known that tumor cells and tumor stromal cells (such as macrophages and thrombocytes) can produce prolymphangiogenic factors, which increase lymphovascular density in and around the tumors [27, 28] , mainly peritumoral regions. Lymph node metastases often occurred in tumors lacking intratumoral functional lymphatics, suggesting that functional lymphatics at the peritumoral regions are the route of lymphatic dissemination. Increased peritumoral lymphovascular density is considered to increase the flow of lymphatic fluid and provide an opportunity for invasive tumor cells to access the lymphatic vessels [29] . This may elucidate our results that LVI is closely related to lymph node metastasis. Moreover, we speculated that LVI may be the precursor of lymph node metastasis. Thus, we divided patients without lymph nodes metastases into LVI positive and LVI negative subgroups, and found that the 5year DFS and OS rates in the LVI negative group were significantly higher than those in the LVI positive group (Figure 2A and B) . This result indicates that LVI is an admirable prognostic predictor for patients with type Ⅳ HC when lymph node metastasis is absent.
Additionally, tumor size > 30 mm was another significant factor correlated with LVI in our series. Tumor size is recognized as a staging basis for many malignant tumors, including thyroid carcinoma, breast carcinoma, and liver carcinoma among others. Gurleyik et al [30] reported that LVI correlated with tumor size, and the rate of LVI positive increased with tumor size in patients with breast carcinoma. The significant correlation between LVI and tumor size could be explained through two potential aspects: (1) as the tumor size increases, the peritumoral areas increase. Thus, the tumor is endowed with the potential to make contact with an increasing lymphovasculature, and thus the possibility of LVI increases; and (2) tumor size is proportional to the time of growth: the larger the tumor, the greater the duration of time that the tumor can continue developing and growing in size. During a relatively longer growth time, a tumor has increasing opportunities to develop LVI. In our study, patients with tumor size ≤ 30 mm were also divided into LVI positive and LVI negative subgroups. Here, the 5year DFS and OS rates in the LVI negative group were significantly higher than those found in the LVI positive group ( Figure 3A and B) . This result indicates that LVI is also an excellent prognostic predictor in type Ⅳ HC patients with smaller tumor size. Some limitations of the study should also be taken into account when interpreting the results. First, our study was retrospective with inherent limitations in its design. Thus, some clinical bias was inevitable. Next, LVI was confirmed by hematoxylin and eosin (HE) staining alone without application of an immunohistochemical staining with D240 antibody, which may improve the detection rate of LVI [31] . Third, N1 stage and tumor size > 30 mm might serve as potential confounding factors that could affect the association between LVI and the eventual prognosis. Finally, we did not carry out preclinical medical experiments to elaborate the specific molecular mechanism that could play a key role in the capacity of LVI to affect the prognosis of type Ⅳ HC patients. Future research should take into account this topic with a greater sample size. Prospective studies, even randomized controlled trials, are also urgently needed. Of course, the specific molecular mechanism responsible for LVI affecting the prognosis of type Ⅳ HC patients will be determined by empirical research.
In conclusion, the presence of LVI may be regarded as an indicator of biologically aggressive behavior, metastatic ability, and regional and systemic risk of metastasizing the primary malignancy. LVI is associated with N1 stage and tumor size > 30 mm and imparts an adverse influence on OS and DFS in type Ⅳ HC patients who received radical resection.
COMMENTS
Background
Despite advances in surgical techniques and that resection rates for Bismuth type Ⅳ hilar cholangiocarcinoma (HC) continue to increase, the prognosis of patients with type Ⅳ HC remains unsatisfactory. The reasons for this remain unclear and seem to be complex and multifactorial. Lymphovascular invasion (LVI) is associated with a poorer prognosis in patients with various malignances. This study sought to investigate whether LVI could predict type Ⅳ HC prognosis.
Research frontiers
This study estimates prognostic factors that might be associated with overall survival (OS) and disease-free survival (DFS) after radical resection in type Ⅳ HC patients. To our knowledge, this study represents the first clinical insight indicating that LVI is associated with the prognosis of type Ⅳ HC.
Innovations and breakthroughs
This findings confirmed that R1 resection, N1 stage, presence of LVI and tumor size > 30 mm were adverse prognostic predictors for type Ⅳ HC patients after radical resection. Further, LVI was found to be associated with N1 stage and tumor size > 30 mm and adversely influence OS and DFS. 
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